The funds described herein are open to “accredited investors” only, through an offering made in accordance with Regulation D, Rule 506(c) of the Securities Act of 1933, as amended. In purchasing securities through a 506(c) offering, we are obligated to verify any participating investor’s status as an “accredited investor” in accordance with Rule 501 of Regulation D. Investors should consider the investment objectives, risks, charges, and expenses of the fund carefully before investing. We do not make any representations as to the accuracy or completeness of the information contained on this website and undertake no obligation to update the information. Past performance is not an indicator of any future results. All investments contain risk and may lose value. This does not constitute an offer to sell or a solicitation of interest to purchase any securities or investment advisory services in any country or jurisdiction in which such offer or solicitation is not permitted by law.

The Future of Medicine – David C. Karli

In this Show

David C. Karli believes he is ahead of what he anticipated. Six years ago he would have never thought that he would reach the level at where he operates today.

Karli takes the body’s natural healing power and manipulates it into a product that can be used to improve patients healing capabilities. He reduces the risk of powerful medications and therapies by working more naturally with the body.

There are therapeutic cells within these preparations that we can use to promote and support natural healing. Our company promotes healing at the end of the day. We apply it towards orthopedic applications: arthritis, sports injuries, things of that nature.

We set up a laboratory processing facility within a hospital or a practice or an academic institution, for example, where we produce the sample that is implanted. We coordinate with the providers to obtain a sample, process it, analyze it, and we’ll get into the quality control component of organization, which is the unique piece, and then re-implant it via the provider. Greyledge cannot practice medicine, we’re a service provider.  It’s a collaborative effort with the clinician.

We’re collaborative service provider, and becoming more of a data management company as well, because it’s our responsibility to validate that our products work, just like any company, in this case it’s a biotech and medical apps company, we create a platform from which we can track our outcomes with our associates, or with our network.

Where Greyledge Technologies and Karli can go from here is completely unlimited.

Get in contact with David C. Karli through his website, LinkedIn, and learn more about Greyledge Technologies here:

(Visited 48 times, 1 visits today)